An end to lawsuit is positive for Novo Nordisk, says analyst
Novo Nordisk gets out of a billion-dollar lawsuit in Denmark without paying plaintiffs or admitting wrongdoing. This is positive, says Analyst Søren Løntoft Hansen.
by marketwire, translated by daniel pedersen
On Friday, pharmaceutical firm Novo Nordisk settled a securities lawsuit in which shareholders had alleged Novo Nordisk had misled them about the insulin sales pressure on the US market and what this would mean for future sales.